Identification of Trypanocidal Activity for Known Clinical Compounds Using a New Trypanosoma cruzi Hit-Discovery Screening Cascade

Manu De Rycker (Lead / Corresponding author), John Thomas, Jennifer Riley, Stephen J. Brough, Tim J. Miles, David W. Gray (Lead / Corresponding author)

Research output: Contribution to journalArticlepeer-review

35 Citations (Scopus)
182 Downloads (Pure)

Abstract

Chagas disease is a significant health problem in Latin America and the available treatments have significant issues in terms of toxicity and efficacy. There is thus an urgent need to develop new treatments either via a repurposing strategy or through the development of new chemical entities. A key first step is the identification of compounds with anti-Trypanosoma cruzi activity from compound libraries. Here we describe a hit discovery screening cascade designed to specifically identify hits that have the appropriate anti-parasitic properties to warrant further development. The cascade consists of a primary imaging-based assay followed by newly developed and appropriately scaled secondary assays to predict the cidality and rate-of-kill of the compounds. Finally, we incorporated a cytochrome P450 CYP51 biochemical assay to remove compounds that owe their phenotypic response to inhibition of this enzyme. We report the use of the cascade in profiling two small libraries containing clinically tested compounds and identify Clemastine, Azelastine, Ifenprodil, Ziprasidone and Clofibrate as molecules having appropriate profiles. Analysis of clinical derived pharmacokinetic and toxicity data indicates that none of these are appropriate for repurposing but they may represent suitable start points for further optimisation for the treatment of Chagas disease.

Original languageEnglish
Article numbere0004584
Number of pages19
JournalPLoS Neglected Tropical Diseases
Volume10
Issue number4
DOIs
Publication statusPublished - 15 Apr 2016

Fingerprint Dive into the research topics of 'Identification of Trypanocidal Activity for Known Clinical Compounds Using a New <i>Trypanosoma cruzi</i> Hit-Discovery Screening Cascade'. Together they form a unique fingerprint.

Cite this